Neil Kumar - 16 May 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BBIO
Reported as of: 16 May 2025
Net transaction value: -$4,488,520
SEC form: 4
Accepted by SEC: 20 May 2025, 18:06:46 UTC
Prior SEC filing: 24 Apr 2025
Next SEC filing: 03 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Neil Kumar

Key filing fact

Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 20 May 2025.

Key facts

This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
8 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 20 May 2025, 18:06.

Change

Previous filing in this sequence was filed on 24 Apr 2025.
Current net transaction value: -$4,488,520.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742485 Primary reporting owner

Kumar Neil

Relationship: Chief Executive Officer, Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Neil Kumar
Signature date: 20 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +64,696
Change %: +31%
Price
Shares after: 276,414
Date: 16 May 2025
Ownership: Direct
Footnotes: F1

BBIO transaction

Common Stock

Tax liability

Transaction value: $1,111,779
Shares: -32,854
Change %: -12%
Price: $33.84
Shares after: 243,560
Date: 16 May 2025
Ownership: Direct
Footnotes: F2

BBIO transaction

Common Stock

Sale

Transaction value: $858,265
Shares: -25,756
Change %: -11%
Price: $33.32
Shares after: 217,804
Date: 19 May 2025
Ownership: Direct
Footnotes: F3, F4

BBIO transaction

Common Stock

Sale

Transaction value: $13,499
Shares: -400
Change %: -0.18%
Price: $33.75
Shares after: 217,404
Date: 19 May 2025
Ownership: Direct
Footnotes: F3, F5

BBIO transaction

Common Stock

Sale

Transaction value: $2,504,978
Shares: -75,000
Change %: -1.5%
Price: $33.40
Shares after: 4,798,447
Date: 20 May 2025
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F3, F6, F7

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 995,686
Date: 16 May 2025
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -33,544
Change %: -12%
Price: $0.000000
Shares after: 234,808
Date: 16 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,544
Exercise price
Footnotes: F1, F8

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -19,599
Change %: -8.3%
Price: $0.000000
Shares after: 215,592
Date: 16 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,599
Exercise price
Footnotes: F1, F9

BBIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -11,553
Change %: -6.2%
Price: $0.000000
Shares after: 173,307
Date: 16 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,553
Exercise price
Footnotes: F1, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 10 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 64,696 shares of Common Stock underlying the Reporting Person's RSUs.

Footnote F3

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

Footnote F4

Represents the weighted average sale price of the shares sold from $32.72 to $33.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F5

Represents the weighted average sale price of the shares sold from $33.72 to $33.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F6

Represents the weighted average sale price of the shares sold from $33.02 to $33.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F7

The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Footnote F8

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Footnote F9

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

Footnote F10

The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.